RATIONALE: It is well established that most patients with chronic rhinosinusitis(CRS) suffer from poor sleep, which is associated with impaired quality of life. However, this has not been studied objectively and the risk factors for sleep disruption in CRS remain unknown. This prospective study aimed to investigate the extent of disturbances and breathing disorders during sleep by using polysomnography(PSG). METHODS: Thirty randomly selected CRS patients underwent overnight PSG and completed 2 sleep-related questionnaires including the Pittsburgh Sleep Quality Index(PSQI) and Munich Circadian Rhythm. CRS characteristics including presence of nasal polyps, sinus tissue histopathology, Lund-Mackay Score(LMS), sinonasal outcome test scores(SNOT-22) and comorbid diseases (asthma, aspirin exacerbated respiratory disease, allergic rhinitis and gastroesophageal reflux[GERD]) were also investigated. PSG results were recorded and compared in association with these variables. RESULTS: Overall, 58.6 % of the patients had apnea-hypopnea index above 5 indicative of obstructive sleep apnea(OSA): 27.6% mild, 13.8% moderate and 17.2% severe. 68% of patients had hypoxemic episodes during sleep. The mean6SD O2 nadir was 77.5623.03 in the whole series. Male gender and GERD were associated with OSA, after adjusting for BMI. Patients with nasal polyp had a trend toward increased supine AHI(adjusted p50.09). OSA was associated with poor sleep quality measured by PSQI and circadian rhythm disruption measured by Munich. CONCLUSIONS: Our prospective study screening with PSG showed that more than half of the CRS patients have OSA, which suggests that all CRS patients potentially need to be screened using PSG, especially male patients and those with comorbid GERD. Further research on cost effectiveness is warranted. Brigham and Women's Hospital, Division of Rheumatology, Immunology, and Allergy, Boston, MA. RATIONALE: The association between sinonasal symptoms and pulmonary function in aspirin-exacerbated respiratory disease (AERD) is not fully established. The aim of this study was to determine if sinonasal symptomatology predicts asthma severity. METHODS: Prospectively collected enrollment and follow-up data from an AERD registry was included from 2013-18. Sino-Nasal Outcomes Test (SNOT) 22-item scores were the predictor variable, with Asthma Control Test (ACT) scores and percent predicted forced expiratory volume in one second (FEV1%) as primary outcome variables. All instances of paired data on the same date were used. ACT was also evaluated with FEV1% as the outcome. Mixed effects regression was completed with SAS 9.4. RESULTS: 1071 AERD patients were in the registry (mean age 47.5y, SD 13.0; 61.9% female, 28.1% male, 10.0% not stated). Mean SNOT-22 score was 42.2 (SD524.2, n51281 observations from 845 patients), mean ACT score was 19.4 (SD5 5.1, n51435 observations from 863 patients), and mean FEV1% was 82.9 (SD 19.8, n5746 observations from 298 subjects). SNOT-22 significantly predicted ACT scores (p<0.0001, 1173 observations from 828 subjects) and FEV1% (p50.011, 473 observations from 242 subjects). Any ten-point increase in SNOT-22 was associated with a 0.87 decrease in ACT and a 0.82 decrease in FEV1%. ACT significantly predicted FEV1%; any one-point increase in ACT was associated with a 0.991 increase in FEV1% (p<0.0001, 599 observations from 260 subjects). CONCLUSIONS: SNOT-22 scores significantly predict ACT scores and FEV1%. ACT scores also significantly predicted FEV1%. This study demonstrates a significant association between rhinosinusitis symptom severity and subjective and objective measures of asthma severity. (50)(51)(52)(53)(54)(55)(56)(57)(58)(59)(60)(61)(62)(63)(64), and elderly subjects (> _65) with NP, and agematched healthy controls were collected. Affymetrix microarray assays were performed using NP and uncinate tissues, and the expression of B cell activation markers was examined. A murine model of NP was generated in 3 age groups: young (2 months), middle-aged (12 months) and old-aged (20 months). Levels of B cell activating factor (BAFF) and anti-dsDNA antibody were measured by ELISA and CD138 (plasma cell marker) was examined using immunohistochemistry. RESULTS: There was increased BAFF protein levels in NLF in mature adults (50-64) with NP compared to controls (75.5 vs 17.2 pg/ml, p50.0198). Levels of anti-dsDNA antibody were significantly increased in older subjects with NP compared to controls (68.8 vs 7.9 IU/ml, p50.003). CD138 staining was greater in NP subjects than controls without age differences. The microarray analysis revealed that gene expressions of TNFRSF13C(BAFF receptor), CD19(B-cell marker), MS4A1(CD20; B-cell marker), SDC1(CD138; plasma cell marker) and TPSB2(MCP-6; mast cell marker) were significantly higher in elderly NP subjects vs elderly controls. In the murine model of NP, BAFF protein levels were significantly increased in NLF compared to controls in the middle-aged NP group (299.2 vs 29.4 pg/ml, p50.007), demonstrating a similar pattern in human NP. CONCLUSIONS: This study demonstrates age-related differences of Bcell inflammatory responses in human NP and a murine NP model. 
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